Respiratory

Following the science to improve patient outcomes

What will make the biggest difference?

Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.



Whether you’re a bench scientist, whether you’re in commercial, whether you’re in development, it’s taking great ideas, innovative science and translating them into medicines that are going to make a transformational difference to patients. That’s what drives us, and that’s what science can do.

Tom Keith-Roach Vice-President, Respiratory



Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Respiratory (as at 27 July 2017)

Phase 1

Phase 1

  • AZD0284 psoriasis/respiratory
  • AZD5634 cystic fibrosis
  • AZD7594 + abediterol asthma/chronic obstructive pulmonary disease
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • AZD9898 asthma
  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • AZD1419 asthma
  • AZD7594 asthma/chronic obstructive pulmonary disease
  • AZD8871 chronic obstructive pulmonary disease
  • PT010 asthma
  • abediterol asthma/chronic obstructive pulmonary disease
  • tezepelumab asthma/atopic dermatitis

Phase 3

Phase 3

  • Bevespi Aerosphere PINNACLE chronic obstructive pulmonary disease
  • PT010 chronic obstructive pulmonary disease
  • benralizumab CALIMA SIROCCO ZONDA BISE BORA GREGALE severe asthma
  • benralizumab TERRANOVA GALATHEA chronic obstructive pulmonary disease
  • tralokinumab STRATOS 1,2 TROPOS MESOS severe asthma

LCM Projects

LCM Projects

  • Duaklir Genuair chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma




Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Accolate, Accoleit, Vanticon zafirlukast
  • Bricanyl Respules terbutaline
  • Bricanyl Turbuhaler terbutaline in a dry powder inhaler
  • Daliresp/Daxas roflumilast
  • Duaklir Genuair aclidinium/formoterol
  • Eklira Genuair/Tudorza/Bretaris aclidinium, a LAMA
  • Oxis Turbuhaler Oxis Turbuhaler
  • Pulmicort Turbuhaler budesonide
  • Pulmicort Respules budesonide inhalation suspension
  • Rhinocort budesonide
  • Symbicort pMDI budesonide/formoterol
  • Symbicort Turbuhaler budesonide/formoterol

Commitment to science

Our commitment to science is reflected in our track record of publications. View recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Our resources


Our focus on unmet medical needs

Improving patient outcomes with tailored therapies, devices, and support tools

  • Global burden of respiratory diseases

    Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)


  • Inhaled therapies and novel combinations

    Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum


  • Targeted biologic therapies

    Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies




Partnering case studies




Veeva ID: Z4-4823
Date of prep: 22/05/2017
Date of expiry: 22/05/2018